Skip to content
Research Article Open access CC BY 4.0

SARS-CoV-2: A Systematic Review

Ravi Babu Birudu, D. Meena Satya Kumari, G. Sangaiah, P. Ratna Sekhar, R. Danya Babu, S. Suma, D. Raju

Asian Journal of Biology · pp. 10–17 · Published 22 Dec 2022

10.9734/ajob/2022/v16i3302

Abstract

Viruses, which are incredibly tiny particles, are what give humans pandemic and epidemic diseases. Many viral infections have impacted human health throughout history, and epidemic and pandemic diseases have claimed many lives. Many viral infections, such as SARS, the Middle East respiratory syndrome corona virus, Ebola, H1N1, and the current COVID-19, have affected people in this decade. Positive sense single-stranded RNA is present in SARS CoV2. The virus's structure is reminiscent of the Corona virus found in bats. SARS-CoV-2, which has its genesis in Wuhan, China's primary transportation hub, is the cause of COVID-19. SARS-CoV-2 spread globally from China. In 213 countries, 1.5 crore people have been diagnosed with COVID-19, and 6.3 lakh of them have died. The primary symptoms include headache, dry cough, myalgia, difficulty breathing, and fever. Serological testing, RT-PCR, and CT-Scan imaging are used to diagnose this condition. Like SARS virus, SARS-CoV-2 virus binds to ACE2 receptors. The same medications used to treat SARS are also utilized to treat COVID-19 patients. Drugs like Remdesivir, Ritonavir-lopinavir, and Umifenovir work well to lower viral loads in patients. The vaccine is being prepared in numerous nations. The COVID-19 disease vaccines are being made by Oxford University (AZD1222), the USA (MRNA-1273), India (COVAXIN), and China (INO-4800). Since the vaccinations are still in the clinical trial stage, we are still waiting for an effective vaccine.

ACE2 receptors CT-image COVID-19 COVAXIN RT-PCR SARS-CoV-2

References (40)

  1. 1 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [DOI]
  2. 2 Clinical Characteristics of Coronavirus Disease 2019 in China [DOI]
  3. 3 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [DOI]
  4. 4 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [DOI]
  5. 5 Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia [DOI]
  6. 6 Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding [DOI]
  7. 7 WHO Declares COVID-19 a Pandemic. [DOI]
  8. 8 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR [DOI]
  9. 9 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [DOI]
  10. 10 First Case of 2019 Novel Coronavirus in the United States [DOI]
  11. 11 Origin and evolution of pathogenic coronaviruses [DOI]
  12. 12 Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 [DOI]
  13. 13 Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 [DOI]
  14. 14 High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa [DOI]
  15. 15 Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection [DOI]
  16. 16 A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) [DOI]
  17. 17 Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes [DOI]
  18. 18 Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) [DOI]
  19. 19 Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? [DOI]
  20. 20 Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection [DOI]
  21. 21 Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS‐CoV‐2 [DOI]
  22. 22 Coronavirus puts drug repurposing on the fast track [DOI]
  23. 23 The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures [DOI]
  24. 24 Genomic variance of the 2019‐nCoV coronavirus [DOI]
  25. 25 Health risks and potential remedies during prolonged lockdowns for coronavirus disease 2019 (COVID-19) [DOI]
  26. 26 Secondary attack rate and superspreading events for SARS-CoV-2 [DOI]
  27. 27 Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China [DOI]
  28. 28 Human coronavirus circulation in the United States 2014–2017 [DOI]
  29. 29 The 2019 novel coronavirus disease (COVID-19) pandemic [DOI]
  30. 30 Pre- and Posttreatment Chest CT Findings: 2019 Novel Coronavirus (2019-nCoV) Pneumonia [DOI]
  31. 31 Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus [DOI]
  32. 32 Cyanobacterial blooms [DOI]
  33. 33 Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia [DOI]
  34. 34 Do we need a Global Virome Project? [DOI]
  35. 35 Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ) [DOI]
  36. 36 Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection [DOI]
  37. 37 La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
  38. 38 The Proceedings of the National Academy of Sciences [DOI]
  39. 39 International Journal of Oral Science [DOI]
  40. 40 National Center for Immunization and Respiratory Diseases (NCIRD) [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

10

Page views

0

PDF downloads

1

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.